Literature DB >> 33980577

CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice.

Yoshinori Yasuda1, Shintaro Iwama2, Daisuke Sugiyama3, Takayuki Okuji1, Tomoko Kobayashi1, Masaaki Ito1, Norio Okada1, Atsushi Enomoto4, Sachiko Ito3, Yue Yan3, Mariko Sugiyama1, Takeshi Onoue1, Taku Tsunekawa1, Yoshihiro Ito1,5, Hiroshi Takagi1, Daisuke Hagiwara1, Motomitsu Goto1, Hidetaka Suga1, Ryoichi Banno1,6, Masahide Takahashi4, Hiroyoshi Nishikawa3,7, Hiroshi Arima1.   

Abstract

Immune-related adverse events induced by anti-programmed cell death-1 antibodies (PD-1-Ab), including destructive thyroiditis (thyroid-irAE), are thought to be caused by activated T cells. However, the T cell subsets that are directly responsible for damaging self-organs remain unclear. To clarify which T cell subsets are involved in the development of thyroid-irAE, a mouse model of thyroid-irAE was analyzed. PD-1-Ab administration 2.5 months after immunization with thyroglobulin caused destructive thyroiditis. Thyroiditis was completely prevented by previous depletion of CD4+ T cells and partially prevented by depleting CD8+ T cells. The frequencies of central and effector memory CD4+ T cell subsets and the secretion of interferon-γ after stimulation with thyroglobulin were increased in the cervical lymph nodes of mice with thyroid-irAE compared with controls. Histopathological analysis revealed infiltration of CD4+ T cells expressing granzyme B in thyroid glands and major histocompatibility complex class II expression on thyrocytes in mice with thyroid-irAE. Adoptive transfer of CD4+ T cells from cervical lymph nodes in mice with thyroid-irAE caused destruction of thyroid follicular architecture in the irradiated recipient mice. Flow cytometric analyses showed that the frequencies of central and effector memory CD4+ T cells expressing the cytotoxic marker CD27 were higher in peripheral blood mononuclear cells collected from patients with thyroid-irAE induced by PD-1-Ab versus those without. These data suggest a critical role for cytotoxic memory CD4+ T cells activated by PD-1-Ab in the pathogenesis of thyroid-irAE.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33980577     DOI: 10.1126/scitranslmed.abb7495

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  9 in total

1.  Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy.

Authors:  Melissa G Lechner; Mandy I Cheng; Anushi Y Patel; Aline T Hoang; Natalie Yakobian; Michael Astourian; Marissa S Pioso; Eduardo D Rodriguez; Ethan C McCarthy; Willy Hugo; Trevor E Angell; Alexandra Drakaki; Antoni Ribas; Maureen A Su
Journal:  J Immunol       Date:  2022-07-11       Impact factor: 5.426

2.  Effects of high-fat diet on thyroid autoimmunity in the female rat.

Authors:  Zhengzheng Liao; Ying Kong; Liang Zeng; Qing Wan; Jinfang Hu; Yaojun Cai
Journal:  BMC Endocr Disord       Date:  2022-07-16       Impact factor: 3.263

3.  Immune Checkpoint Inhibitor-related Endocrinopathies.

Authors:  Difei Lu; Ying Gao
Journal:  J Transl Int Med       Date:  2022-04-02

4.  T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.

Authors:  Alexander X Lozano; Aadel A Chaudhuri; Aishwarya Nene; Aaron M Newman; Antonietta Bacchiocchi; Noah Earland; Matthew D Vesely; Abul Usmani; Brandon E Turner; Chloé B Steen; Bogdan A Luca; Ti Badri; Gunsagar S Gulati; Milad R Vahid; Farnaz Khameneh; Peter K Harris; David Y Chen; Kavita Dhodapkar; Mario Sznol; Ruth Halaban
Journal:  Nat Med       Date:  2022-01-13       Impact factor: 87.241

5.  Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients.

Authors:  Kota Iwahori; Takeshi Uenami; Yukihiro Yano; Toshihiko Ueda; Mari Tone; Yujiro Naito; Yasuhiko Suga; Kiyoharu Fukushima; Takayuki Shiroyama; Kotaro Miyake; Shohei Koyama; Haruhiko Hirata; Izumi Nagatomo; Hiroshi Kida; Masahide Mori; Yoshito Takeda; Atsushi Kumanogoh; Hisashi Wada
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

Review 6.  Immune-checkpoint inhibitors: long-term implications of toxicity.

Authors:  Douglas B Johnson; Caroline A Nebhan; Javid J Moslehi; Justin M Balko
Journal:  Nat Rev Clin Oncol       Date:  2022-01-26       Impact factor: 65.011

Review 7.  Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1.

Authors:  Yuwei Hao; Matthew C Cook
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

8.  TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice.

Authors:  Jian Gao; Jinlin Miao; Haoyang Sun; Xianghui Fu; Peiyan Zhang; Zhinan Chen; Ping Zhu
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

Review 9.  Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.

Authors:  Adrian Chye; India Allen; Megan Barnet; Deborah L Burnett
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.